Abbott Laboratories (ABT) is listed on NYSE in the Healthcare sector Β· Medical Devices industry. The current price is 108.68, down -1.62% from the previous close. Market cap is approximately $189.3B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
ABT's 35.17x P/E is in premium territory. Justifiable while growth accelerates, but this is also the band that reacts first to guidance cuts or macro shocks.
An ROE of 10.58% is standard territory. Without a clear differentiator, expect the figure to drift toward the industry mean over time.
ABT's D/E at 63.21 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
Abbott Laboratories's 13.00% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
ABT's 2.28% yield fits an income-with-growth posture.
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Abbott Laboratories trades near the midpoint (52%) of its 52-week range (81.97β137.49). With the price anchored to neither extreme, valuation and earnings tend to be more informative than price direction here.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The day's high-to-low spread reached 3.66%, with a -1.62% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Abbott Laboratories (ABT) is listed on NYSE, with recent volume of 1,631,527 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.